TerThera has installed its first production line dedicated exclusively to terbium-161 (Tb-161), a radioactive isotope being developed for targeted cancer treatments.
TerThera is a pharmaceutical manufacturer that develops and supplies terbium-based radioisotopes for targeted radionuclide therapy and radiopharmaceutical applications.
The installation involved Comecer, whose assembly team was responsible for building the production line.
TerThera said the assembly was completed using a lean process designed to maximise efficiency.
The company said the dedicated line will support the production of GMP-grade Tb-161, with the facility intended to provide a reliable supply of the radioisotope for use in the development and manufacture of targeted radiopharmaceuticals.
Once operational, the line is expected to enable daily production of Tb-161 and supply customers globally.
The newly installed production infrastructure forms part of TerThera’s wider manufacturing setup for Tb-161, with the company targeting increased availability of the radioisotope for the radiopharmaceutical sector.
